Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  13,547 results for ""Cytochrome P-450 CYP3A""

Your Filters

Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Value of Assessing 1-Hydroxymidazolam in Drug-Drug Interaction Studies with Midazolam as a Substrate of Cytochrome P450 3A.

  • Authors : Magliocca M; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.; Berger B

Subjects: Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/metabolism ; Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/administration & dosage ; Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/pharmacokinetics

  • Source: Journal of clinical pharmacology [J Clin Pharmacol] 2024 Sep; Vol. 64 (9), pp. 1123-1129. Date of Electronic Publication: 2024 May 26.Publisher: Wiley Country of Publication: England NLM ID: 0366372 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-4604

Record details

Read More Add to Saved list
×
Academic Journal

1β-Hydroxydeoxycholic Acid as an Endogenous Biomarker in Human Plasma for Assessment of CYP3A Clinical Drug-Drug Interaction Potential.

  • Authors : Xue Y; Clinical Pharmacology, Pharmacometrics & Bioanalysis, Bristol-Myers Squibb, Princeton, New Jersey (Y.X., L.W., R.H., B.M., A.G., J.X.S.); Regeneron Pharmaceuticals Inc., Tarrytown, New York (M.C.)

Subjects: Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/metabolism ; Drug Interactions* ; Biomarkers*/Biomarkers*/Biomarkers*/blood

  • Source: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2024 Aug 14; Vol. 52 (9), pp. 966-974. Date of Electronic Publication: 2024 Aug 14.Publisher: American Society for Pharmacology and Experimental Therapeutics, etc.] Country of Publication: United States NLM ID: 9421550 Publication Model:

Record details

Read More Add to Saved list
×
Academic Journal

Drug-induced enzyme activity inhibition and CYP3A4 genetic polymorphism significantly shape the metabolic characteristics of furmonertinib.

  • Authors : Zhou Q; Institute of Molecular Toxicology and Pharmacology, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.; Ye Z

Subjects: Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/genetics ; Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/metabolism ; Rats, Sprague-Dawley*

  • Source: Toxicology [Toxicology] 2024 Sep; Vol. 507, pp. 153903. Date of Electronic Publication: 2024 Aug 03.Publisher: Elsevier Country of Publication: Ireland NLM ID: 0361055 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-3185

Record details

Read More Add to Saved list
×
Academic Journal

A drug-drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5-lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam.

  • Authors : Knöchel J; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; Panduga V

Subjects: Midazolam*/Midazolam*/Midazolam*/pharmacokinetics ; Midazolam*/Midazolam*/Midazolam*/administration & dosage ; Drug Interactions*

  • Source: British journal of clinical pharmacology [Br J Clin Pharmacol] 2024 Sep; Vol. 90 (9), pp. 2180-2187. Date of Electronic Publication: 2024 Jun 03.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

An open-label study to explore the optimal design of CYP3A drug-drug interaction clinical trials in healthy Chinese people.

  • Authors : Chen J; Research Ward, Beijing Friendship Hospital, Capital Medical University, Beijing, China.; Li J

Subjects: Drug Interactions* ; Midazolam*/Midazolam*/Midazolam*/pharmacokinetics ; Midazolam*/Midazolam*/Midazolam*/administration & dosage

  • Source: Pharmacology research & perspectives [Pharmacol Res Perspect] 2024 Aug; Vol. 12 (4), pp. e1252.Publisher: John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics Country of Publication: United States

Record details

Read More Add to Saved list
×
Academic Journal

Docetaxel, cyclophosphamide, and epirubicin: application of PBPK modeling to gain new insights for drug-drug interactions.

  • Authors : Li T; Phase I Clinical Trial Unit, The First Affiliated Hospital With Nanjing Medical University, Nanjing, 210029, China.; Department of Clinical Pharmacology, School of Pharmacy College, Nanjing Medical University, Nanjing, 211166, China.

Subjects: Drug Interactions* ; Epirubicin*/Epirubicin*/Epirubicin*/pharmacokinetics ; Epirubicin*/Epirubicin*/Epirubicin*/administration & dosage

  • Source: Journal of pharmacokinetics and pharmacodynamics [J Pharmacokinet Pharmacodyn] 2024 Aug; Vol. 51 (4), pp. 367-384. Date of Electronic Publication: 2024 Mar 30.Publisher: Springer Country of Publication: United States NLM ID: 101096520 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Lack of CYP3A4 protein induction despite mRNA induction in primary hepatocytes exposed to rifabutin as a possible explanation for its low interaction risk in vivo.

  • Authors : Nilles J; Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.; Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharma GmbH and Co. KG, Birkendorfer Str. 65, 88397, Biberach an der Riss, Germany.

Subjects: Rifabutin*/Rifabutin*/Rifabutin*/analogs & derivatives ; Rifabutin*/Rifabutin*/Rifabutin*/toxicity ; Hepatocytes*/Hepatocytes*/Hepatocytes*/drug effects

  • Source: Archives of toxicology [Arch Toxicol] 2024 Aug; Vol. 98 (8), pp. 2541-2556. Date of Electronic Publication: 2024 May 07.Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 0417615 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Identification of reversible OATP1B1 and time-dependent CYP3A4 inhibition as the major risk factors for drug-induced cholestasis (DIC).

  • Authors : Kastrinou-Lampou V; Pharmacokinetic Sciences, BioMedical Research, Novartis, Basel, Switzerland.; Preclinical Safety, BioMedical Research, Novartis, Basel, Switzerland.

Subjects: Cholestasis*/Cholestasis*/Cholestasis*/chemically induced ; Cholestasis*/Cholestasis*/Cholestasis*/metabolism ; Liver-Specific Organic Anion Transporter 1*/Liver-Specific Organic Anion Transporter 1*/Liver-Specific Organic Anion Transporter 1*/metabolism

  • Source: Archives of toxicology [Arch Toxicol] 2024 Oct; Vol. 98 (10), pp. 3409-3424. Date of Electronic Publication: 2024 Jul 18.Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 0417615 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Effect of Carbamazepine on the Pharmacokinetics of Erdafitinib in Healthy Participants.

  • Authors : Jaiprasart P; Clinical Pharmacology & Pharmacometrics, Janssen Research & Development, North Wales, PA, USA.; Hellemans P

Subjects: Drug Interactions* ; Healthy Volunteers* ; Carbamazepine*/Carbamazepine*/Carbamazepine*/pharmacology

  • Source: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2024 Aug; Vol. 13 (8), pp. 852-860. Date of Electronic Publication: 2024 May 13.Publisher: Wiley Country of Publication: United States NLM ID: 101572899 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Effect of cytochrome P450 3A4 on tissue distribution of humantenmine, koumine, and gelsemine, three alkaloids from the toxic plant Gelsemium.

  • Authors : Long JY; College of Veterinary Medicine, Hunan Agricultural University, Changsha, Hunan 410128, China; Hunan Engineering Technology Research Center of Veterinary Drugs, Hunan Agricultural University, Changsha, Hunan 410128, China.

Subjects: Gelsemium*/Gelsemium*/Gelsemium*/chemistry ; Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/metabolism ; Indole Alkaloids*/Indole Alkaloids*/Indole Alkaloids*/toxicity

  • Source: Toxicology letters [Toxicol Lett] 2024 Jun; Vol. 397, pp. 34-41. Date of Electronic Publication: 2024 May 09.Publisher: Elsevier Country of Publication: Netherlands NLM ID: 7709027 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
  • 1-10 of  13,547 results for ""Cytochrome P-450 CYP3A""